Citations

Clear

5 citation(s) found for "Srinivasan, Anand".

Fetal hemoglobin dysregulation in inherited and acquired bone marrow failure syndromes
Heigh, Victoria, Abdelmagid, Maymona, Ongie, Laura, McCullough, Kristen, Fernandez, Jenna, Lasho, Terra, Finke, Christy, Srinivasan, Anand, Kohorst, Mira, Ferdjallah, Asmaa, Hogan, William, Go, Ronald, Dingli, David, Gangat, Naseema, Al-Kali, Aref, Begna, Kebede, Alkhateeb, Hassan, Shah, Mithun, Litzow, Mark, Torghabeh, Mehrdad Hefazi, Matin, Aasiya, Reichard, Kaaren, Dalland, Joanna, Kusne, Yael, Foran, James, Ferrer, Alejandro, Patnaik, Mrinal, Mangaonkar, Abhishek, Heigh, Victoria, Abdelmagid, Maymona, Ongie, Laura, McCullough, Kristen, Fernandez, Jenna, Lasho, Terra, Finke, Christy, Srinivasan, Anand, Kohorst, Mira, Ferdjallah, Asmaa, Hogan, William, Go, Ronald, Dingli, David, Gangat, Naseema, Al-Kali, Aref, Begna, Kebede, Alkhateeb, Hassan, Shah, Mithun, Litzow, Mark, Torghabeh, Mehrdad Hefazi, Matin, Aasiya, Reichard, Kaaren, Dalland, Joanna, Kusne, Yael, Foran, James, Ferrer, Alejandro, Patnaik, Mrinal, Mangaonkar, Abhishek

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6750-6750

10.1182/blood-2025-6750 Get It

Abstract Introduction: Inherited & acquired bone marrow failure syndromes (BMFS) have “stress erythropoiesis” with macrocytic anemia, elevated fetal hemoglobin (HbF) & erythropoietin (EPO) levels. The degree of HbF elevation & its capacity to discriminate between patients with inherited & acquired BMFS needs to be systemically studied. Genetic testing is often delayed & it is important to establish an early clinical diagnosis to make clinical decisions such as initiation of immunosuppressive therapy. Methods: After institutional review board approval, we compiled a clinically & genetically well-annotated cohort of patients with BMFS evaluated at Mayo Clinic. All patients were required to have at least cytopenia(s) & evidence of low or variable bone marrow cellularity upon a bone marrow evaluation. Patients with pre-clonal or malignant disorders were excluded. Clinical diagnoses were independently verified for accuracy. Detailed clinical & laboratory features were recorded. Germline genetic testing was performed as clinically appropriate on peripheral blood or bone marrow samples through targeted panels. Distribution of continuous variables was statistically compared using nonparametric (Mann-Whitney or Kruskal-Wallis) tests, while nominal variables were compared using the Chi-Square test. Kaplan-Meier estimate of overall survival (OS) was computed from the date of diagnosis to date of death or last follow-up (also censored at the time of allogeneic hematopoietic stem cell transplant). Results: Between years 1998 - 2023, 129 patients met criteria for inclusion in the study. Among these, clinical diagnoses included immune-mediated aplastic anemia (AA, n=56, 43%, 21% severe or very severe as per the Camitta criteria), telomere biology disorders (TBD, n=37, 29%), Fanconi anemia (n=10, 8%), GATA2 haploinsufficiency (n=8, 6%), Diamond-Blackfan anemia (DBA, n=2, 2%), deficiency of adenosine deaminase-2 (DADA2, n=2, 2%), congenital dyserythropoietic anemia (CDA, n=1, 1%), congential amegakaryocytic thrombocytopenia (CAMT, n=1, 1%), Schwachman-Diamond syndrome (n=1, 1%) & undefined (n=11, 9%). Among the inherited group, 63% had an identifiable germline pathogenic variant (most commonly, TERT/TERC 30%, FANC group 25% & GATA2 15%) with the rest diagnosed on a clinical basis. Elevated HbF >1% was noted in 79% of all BMFS patients; 83% AA, 70% TBD, 50% in DADA2 & 67% in undefined patients (no data was available for other inherited subtypes). In patients with an elevated HbF, absolute monocyte count (p=0.04) was significantly higher; however, there were no other significant associations with variables at diagnosis such as hemoglobin (p=0.5), white blood cell count (WBC, p=0.14), absolute neutrophil count (p=0.5), platelet count (p=0.7), mean corpuscular volume (MCV, p=0.2), absolute lymphocyte count (p=0.1), absolute reticulocyte count (p=0.4), EPO level (p=0.3), presence of a PNH clone (p=0.2), or presence of a germline variant (p=0.3). When diseases were grouped into inherited & acquired (AA) subgroups, median HbF was not significantly different (median%, 4.5 versus 2.3, p=0.4), with elevated HbF (>1%) in 75% versus 83% (p=0.6) patients respectively. On the other hand, minor PNH clone (>0.1% in at least two cell types) was detectable in the acquired group only (0 versus 55%, p<0.0001). Similarly, acquired group had a shorter (<3 months) onset of cytopenias preceding diagnosis (P<0.0001), with no significant differences in MCV (p=0.2), marrow dysplasia (p=0.09) or atypia (p=0.6), & splenomegaly (p=0.9). At median follow-up of 7 years, Kaplan-Meier estimate of transplant-censored median OS was lower in inherited versus acquired group (16 years versus median not reached, p=0.02). Elevated HbF did not significantly predict adverse OS in either group. Conclusions: Fetal hemoglobin is elevated in both patients with inherited & acquired (aplastic anemia) BMFS. When compared to established variables, elevated HbF has neither diagnostic utility nor prognostic relevance in predicting adverse outcomes. On the other hand, onset of cytopenias and presence of a minor PNH clone are both useful clinical variables in differentiating patients with inherited from acquired BMFS. Our data offers practical clinical utility in making early treatment decisions for patients with BMFS.
We're not talking about sex: Hematopoietic stem cell transplant provider practices and barriers to sexual health discussions with adolescents and young adults
Kimball, Brittany, Kohorst, Mira, Ferdjallah, Asmaa, Srinivasan, Anand, Nordhues, Hannah, Dingli, David, Alkhateeb, Hassan, Durani, Urshila, Kimball, Brittany, Kohorst, Mira, Ferdjallah, Asmaa, Srinivasan, Anand, Nordhues, Hannah, Dingli, David, Alkhateeb, Hassan, Durani, Urshila

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2872-2872

10.1182/blood-2025-2872 Get It

Abstract Introduction: Sexual health is an important part of overall well-being for adolescents and young adults (AYAs) after hematopoietic stem cell transplantation (HCT). AYAs have unique sexual health needs as they navigate development, relationships, and identity formation. AYA patients may experience sexual dysfunction due to conditioning chemotherapy/radiation therapy, graft-versus-host disease (GVHD), changes in body image, mental health effects, relationship shifts, and the challenges of dating with a serious illness. We surveyed both pediatric and adult HCT providers at our institution to assess current practices of discussing sexual health needs with AYAs as well as barriers to these discussions in order to guide interventions to improve communication. Methods: Adult and pediatric HCT physicians, advanced practice providers, and nurse coordinators in the Mayo Clinic Rochester HCT program completed an online survey to understand their perspectives about addressing sexual health needs in AYA HCT survivors. This survey covered current practice patterns in discussing sexual health and managing sexual health needs, barriers to providing sexual health care, and recommendations for provider education. Results: This survey included responses from 25 HCT providers (35% response rate): 22 adult providers and 3 pediatric providers. The respondents comprised of 10 physicians (40%), 8 advanced practice providers (32%), and 7 nurses (28%). Most of the providers saw 6-10 AYA patients per month (48%), while others reported: 1-5 AYAs (36%), 11-15 AYAs (12%), and 16-20 AYAs (4%); no provider saw 21 or more. While all respondents felt sexual health was an important topic for AYA HCT patients, most (80%) also reported rarely (44%) or only sometimes (36%) discussing sexual health with AYA patients. Primary barriers included inadequate knowledge of resources for referrals (72%), insufficient training on this topic (60%), limited time for discussion (56%), discomfort discussing sexual health with AYAs (32%), and concern about patient discomfort (28%). When it came to screening for GVHD, 28% of respondents reported not regularly screening for genitourinary GVHD and 40% indicated feeling uncomfortable or very uncomfortable managing it. Frequently discussed topics included fertility (64%) and contraception (52%). Almost all respondents (96%) expressed interest in further education. Topics of interest included an overview of common sexual health issues in AYA HCT survivors (88%), medical management of sexual health concerns such as erectile dysfunction, low libido, and vaginal dryness (72%), management of psychosocial concerns impacting body image and relationships (64%), cultural considerations for addressing sexual health (56%), providing inclusive care for lesbian, gay, bisexual, trans, queer or questioning (LGBTQ) AYAs (56%), genitourinary GVHD (56%), and safer sex practices during and after transplant (52%). Discussion: Although regular sexual health assessment in HCT survivors is recommended, most providers at our institution did not routinely discuss sexual health with AYAs. While genitourinary GVHD is an important HCT-specific sexual health topic, screening for this condition is not consistently performed. Providers were eager for further education and identified several topic areas for future educational interventions. Our data will aid in the development of an educational intervention for providers covering key sexual health issues in AYA HCT survivors, including medical and psychosocial management of sexual health concerns, as well as inclusive care for intercultural and LGBTQ AYAs, with the aim of improving frequency of sexual health discussions and provider confidence. Time constraints were identified as a key barrier, so patient-focused educational interventions that can occur outside of the clinical appointment may be an opportunity to deliver information and empower patients to raise specific concerns during their visits. In combination with healthcare provider-focused education, this may promote critical sexual health-related discussions during appointments.
Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol
Martin, Catherine E. , O’Keefe, Madeleine, Gullickson, Taylor, Kohorst, Mira A. , Galardy, Paul J. , McAllister, Linda, Kalmes, Jessica L., Kuhn, Alexis , O'Keefe, Madeleine B, Srinivasan, Anand , Galardy, Paul J , Kuhn, Alexis K , DeFino, Catherine E. , Srinivasan, Anand , McAllister, Linda, Kalmes, Jessica

Mayo Clinic

Pediatric Blood & Cancer | September 17, 2025 | Volume: 72 | Issue: 12 | Pages: No page available

10.1002/pbc.32030 | PMID 40958754 Get It

IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria
Srinivasan, Anand , Zhou, Yaolin , Scordino, Teresa , Wierenga, Andrea, Simon, Garfield A., Wierenga, Klaas J. , Thompson, Joel , Shah, Rikin, Sinha, Arpan A. , Sinha, Arpan A , Srinivasan, Anand , Prabhu, Sandeep, Thompson, Joel

Mayo Clinic

Pediatric Hematology and Oncology | March 13, 2020 | Volume: 37 | Issue: 5 | Pages: 431-437

10.1080/08880018.2020.1737284 | PMID 32166993 Get It

Proteomic Analysis of the Human Anterior Pituitary Gland
Yelamanchi, Soujanya D. , Tyagi, Ankur , Mohanty, Varshasnata , Korbonits, Márta , Chavan, Sandip , Advani, Jayshree , Madugundu, Anil K. , Dey, Gourav , Rajyalakshmi, M., Sahasrabuddhe, Nandini A., Chaturvedi, Abhishek , Kumar, Amit , Das, Apabrita Ayan , Ghosh, Dhiman , Jogdand, Gajendra M. , Haritha, Nair Hariprasad , Saini, Keshav , Panchal, Manoj, Sarvaiya, Mansi Ashwinsinh, Mohanraj, Soundappan S. , Sengupta, Nabonita, Saxena, Priti , Subramani, Pradeep Annamalai , Kumar, Pradeep , Akkali, Rakhil, Reshma, S.V., Santhosh, Ramachandran Sarojini , Kumar, Sudarshan , Ghosh, Susanta Kumar , Irlapati, Vamshi K., Srinivasan, Anand, Radotra, Bishan, Mathur, Premendu P. , Wong, G. William , Satishchandra, Parthasarathy, Chatterjee, Aditi , Bhansali, Anil , Pandey, Akhilesh , Shankar, Susarla Krishna, Mahadevan, Anita , Prasad, Thottethodi Subrahmanya Keshava , Pandey, Akhilesh , Pandey, Akhilesh , Prasad, Thottethodi Subrahmanya Keshav , Dutta, Pinaki R , Datta, Keshava K. , Rajyalakshmi, M., Rastogi, Sangita , Srinivasan, Anand, Gowda, Harsha

Mayo Clinic

OMICS: A Journal of Integrative Biology | December 20, 2018 | Volume: 22 | Issue: 12 | Pages: 759-769

10.1089/omi.2018.0160 | PMID 30571610 Get It

Abstract The pituitary function is regulated by a complex system involving the hypothalamus and biological networks within the pituitary. Although the hormones secreted from the pituitary have been well studied, comprehensive analyses of the pituitary proteome are limited. Pituitary proteomics is a field of postgenomic research that is crucial to understand human health and pituitary diseases. In this context, we report here a systematic proteomic profiling of human anterior pituitary gland (adenohypophysis) using high-resolution Fourier transform mass spectrometry. A total of 2164 proteins were identified in this study, of which 105 proteins were identified for the first time compared with high-throughput proteomic-based studies from human pituitary glands. In addition, we identified 480 proteins with secretory potential and 187 N-terminally acetylated proteins. These are the first region-specific data that could serve as a vital resource for further investigations on the physiological role of the human anterior pituitary glands and the proteins secreted by them. We anticipate that the identification of previously unknown proteins in the present study will accelerate biomedical research to decipher their role in functioning of the human anterior pituitary gland and associated human diseases.